取栓后灌注改善与溶栓时间窗及醒后卒中的疗效关联:EXTEND与EPITHET随机试验的荟萃分析
该个体患者荟萃分析纳入EXTEND和EPITHET两项随机试验,评估灌注成像筛选的缺血性卒中患者在接受阿替普酶或安慰剂后,再灌注与90天功能结局的关联。
要点
- 再灌注与90天功能改善显著相关(共同比值比7.7)。
- 4.5-6小时、6-9小时及醒后卒中三个时间层均获益一致。
核心结论
- 再灌注在所有时间层均带来强获益且不增加症状性出血风险,支持灌注错配筛选患者在整个4.5-9小时及醒后卒中时间窗接受阿替普酶治疗的一致疗效。
研究设计与样本
- EXTEND和EPITHET随机临床试验的个体患者荟萃分析,纳入发病4.5-9小时或醒后卒中且经灌注错配成像筛选的患者,随机接受阿替普酶或安慰剂,随访3个月。
主要发现
- 再灌注组中位年龄76(66-81)岁,无再灌注组74(64.5-81.0)岁;基线NIHSS中位数分别为10(7-15)和12(8.0-17.5)。
关键数值与推荐
- 再灌注定义为24-72小时随访时Tmax>6秒病灶体积减少>90%。
- 症状性出血定义为大实质血肿伴NIHSS评分增加≥4分。
临床怎么用
- 对于灌注错配筛选的4.5-9小时或醒后卒中患者,再灌注与功能改善相关且症状性出血风险无差异,支持阿替普酶治疗。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Intravenous alteplase reduces disability after ischemic stroke in patients 4.5 to 9 hours after onset and with wake-up onset stroke selected using perfusion imaging mismatch. However, whether the benefit is consistent across the 4.5- to 6-hours, 6- to 9-hours, and wake-up stroke epochs is uncertain. OBJECTIVE: To examine the association of reperfusion with reduced disability, including by onset-to-randomization time strata in the Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND) and Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) randomized clinical trials. DESIGN, SETTING, AND PARTICIPANTS: Individual patient meta-analysis of randomized clinical trials performed from August 2001 to June 2018 with 3-month follow-up. Patients had acute ischemic stroke with 4.5-to 9-hours poststroke onset or with wake-up stroke were randomized to alteplase or placebo after perfusion mismatch imaging. Analysis began July 2019 and ended May 2020. EXPOSURES: Reperfusion was defined as more than 90% reduction in time to maximum of more than 6 seconds' lesion volume at 24- to 72-hour follow-up. MAIN OUTCOMES AND MEASURES: Ordinal logistic regression adjusted for baseline age and National Institutes of Health Stroke Scale score was used to analyze functional improvement in day 90 modified Rankin Scale score overall, including a reperfusion × time-to-randomization multiplicative interaction term, and in the 4.5- to 6-hours, 6- to 9-hours, and wake-up time strata. Symptomatic hemorrhage was defined as large parenchymal hematoma with a National Institutes of Health Stroke Scale score increase of 4 points or more. RESULTS: Reperfusion was assessable in 270 of 295 patients (92%), 68 of 133 (51%) in the alteplase group, and 38 of 137 (28%) in the placebo reperfused group (P < .001). The median (interquartile range) age was 76 (66-81) years in the reperfusion group vs 74 (64.5-81.0) years in the group with no reperfusion. The median (interquartile range) baseline National Institutes of Health Stroke Scale score was 10 (7-15) in the reperfusion group vs 12 (8.0-17.5) in the no reperfusion group. Overall, reperfusion was associated with improved functional outcome (common odds ratio, 7.7; 95% CI, 4.6-12.8; P < .001). Reperfusion was associated with significantly improved functional outcome in each of the 4.5- to 6-hours, 6- to 9-hours, and wake-up time strata, with no evidence of association between time to randomization and beneficial effect of reperfusion (P = .63). Symptomatic hemorrhage, assessed in all 294 patients, occurred in 3 of 51 (5.9%) in the 4.5- to 6-hours group, 2 of 28 (7.1%) in the 6- to 9-hours group, and 4 of 73 (5.5%) in the wake-up stroke in patients treated with alteplase (Fisher P = .91). CONCLUSIONS AND RELEVANCE: Strong benefits of reperfusion in all time strata without differential risk in symptomatic hemorrhage support the consistent treatment effect of alteplase in perfusion mismatch-selected patients throughout the 4.5- to 9-hours and wake-up stroke time window.
引用
- Campbell BCV, Ma H, Parsons MW, et al. Association of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5- to 9-Hours and Wake-up Stroke Time Window: A Meta-Analysis of the EXTEND and EPITHET Randomized Clinical Trials. JAMA Neurol. 2021. PMID: 33137171. doi:10.1001/jamaneurol.2020.4123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。